Антагонист кальция лерканидипин при артериальной гипертензии

Обложка

Цитировать

Полный текст

Аннотация

В статье представлены результаты исследований по изучению эффективности и безопасности антагониста кальция III поколения лерканидипина в лечении артериальной гипертензии. Лечение лерканидипином приводит к выраженному достоверному снижению систолического и диастолического артериального давления без существенного влияния на частоту сердечных сокращений. Препарат обладает органопротективным действием, уменьшает гипертрофию левого желудочка, улучшает функцию почек и оказывает антипротеинурическое действие. Лерканидипин хорошо переносится, реже вызывает периферические отеки по сравнению с другими антагонистами кальция.

Об авторах

Галина Анатольевна Барышникова

ФГБУ Учебно−научный медицинский центр Управления делами Президента Российской Федерации

д-р мед. наук, проф. каф. семейной медицины ФГБУ УНМЦ УД Президента РФ

Светлана Алексеевна Чорбинская

ФГБУ Учебно−научный медицинский центр Управления делами Президента Российской Федерации

д-р мед. наук, проф., зав каф. семейной медицины ФГБУ УНМЦ УД Президента РФ

Ирина Ираклиевна Степанова

ФГБУ Учебно−научный медицинский центр Управления делами Президента Российской Федерации

канд. мед. наук, доц. каф. семейной медицины ФГБУ УНМЦ УД Президента РФ

Список литературы

  1. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (четвертый пересмотр), 2010.
  2. Mancia G, Fagard R, Narkiewicz K et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925-38.
  3. James P.A, Oparil S, Carter B.L et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.
  4. Angeli F et al. Calcium channel blockade to prevent stroke in hypertension: a meta - analysis of 13 studies with 103 793 subjects. Am J Hypertens 2004; 17 (9): 817-22.
  5. Angelico P, Guarneri L, Leonardi A et al. Vascular - selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharmacol 1999; 51: 709-14.
  6. Herbette L.G, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: Short Plasma Half-Life, Long Duration of Action and High Cholesterol Tolerance. Updated Molecular Model to Rationalize its Pharmacokinetic Properties. Blood pressure. (Suppl.) 1998; 2: 10-7.
  7. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95-100.
  8. Fogari R, Mugellini A, Zoppi A et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9.
  9. Bang L.M, Chapman T.M, Goa K.L. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449-72.
  10. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow - release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31-35.
  11. Cavallini A. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double - blind pilot study. Curr Ther Res 2000; 61 (7): 477-87.
  12. De Giorgio L.A, Orlandini F, Malasoma P et al. Double - blind, crossover study of lercanidipine versus amlodipine in the treatment of mild - to - moderate essential hypertension. CurrTher Res 1999; 60: 511-20.
  13. Zanchetti A. Emerging data on calcium - channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl. 2): II 17-20.
  14. Sironi G, Colombo D, Greto L et al. Regional vasodilating effects of lercanipine in dogs. ISHR XVI World Congress 1998.
  15. Sabbatini M, Tomassoni D, Amenta F. Influence of treatment with Ca2+ antagonistis on cerebral vasculature of spontaneously hypertensive rats. Mechanisms of Ageing and Development 2001; 122: 795-809.
  16. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 8: 92-101.
  17. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62 (5): 723-8.
  18. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: 203-12.
  19. Marx A, Lichtenthal A, Milbredt C et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens 2004; 22 (Suppl. 2): S236.
  20. Barrios V, Calderon A, Navarro A et al. Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. J Hypertens 2004; 17 (9): 823-7.
  21. Sangiorgi B.G, Putignano E, Calcara L, Barbagallo M. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double - blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S36-S39.
  22. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double - blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26-S30.
  23. Aranda P, Aranda F.T, Bianchi J.L et al. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild - moderate essential hypertensives (abstract). J Hyper tens 2000; 18 (Suppl. 2): S152.
  24. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipinevs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients (abstract P1.191). J Hypertens 2000; 18 (Suppl. 2): S65.
  25. Sanchez A, Sayans R, Alvarez J.L et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril (abstract 12). Fourth European Meeting on Calcium Antagonists Amsterdam 1999.
  26. Dworkin Ld. Effects of calcium channel blockers on experimental glomerular injury. J Am Soc Nephrol 1990; 1: S21-27.
  27. Viberti G. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure - Independent Effect. Wheeldon and for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002; 106: 672-8.
  28. Kloke H.J et al. Meta - analysis of changes in albuminuria and arterial pressure in hypertensive patients with proteinuria in studies where patients received nifedipine, any other DHP CCB, a non-DHP CCB, or an ACE inhibitor. Kidney Int 1998; 53: 1559-73.
  29. Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158-65.
  30. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17 (5): 259-66.
  31. Robles N.R, Ocon J, Gomez C.F et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA study. Ren Fail 2005; 27 (1): 73-80.
  32. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arteriolesin spontaneously hypertensive rats. Hypertension 2000; 35 (3): 775-9.
  33. Cafiero M, Giasi M. Long - term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S45-49.
  34. Borghi C, Prandin M.G, Dormi A. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients (abstract. J Hypertens 2000; 18 (Suppl. 2): S155.
  35. Fogari R, Malamani G.D, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double - blind, randomized, parallel - group study. Curr Ther Res 2000; 61 (12): 850-62.
  36. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003; 21: 1003-10.
  37. Rengo F, Romis L. Activity of lercanidipine in double - blind comparison with nitrendipine in combination treatment of resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S54-58.
  38. Marx A, Lichtenthal A, Milbredt C et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens 2004; 22 (Suppl. 2): S236.
  39. Sironi G, Montagna E, Greto L et al. Haemodynamic effects of lercanidipine in anaesthetized open - chest dogs. Arzneim-Forsch Drug Res 1996; 46: 256-61.
  40. Specchia G, Saccaggi S.P, Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res 2001; 62: 3-15.
  41. Ortiz M, Calcino G. Inferred mortality differences between dihydropyridine antihypertensives. Hypertension 2009; 53: 1116.
  42. Isla S Mackenzie, Carmel M, Mc Eniery et al. Comparison of the Effects of Antihypertension Agents on Central Blood pressure and Arterial Stiffness in Isilated Systolic Hypertension. Hypertension 2009; 54: 409-13.

© ООО "Эко-Вектор", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах